<DOC>
	<DOCNO>NCT00045136</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Holmium Ho 166 DOTMP may deliver radiation directly cancer cell cause less damage normal tissue . Combining chemotherapy holmium Ho 166 DOTMP peripheral stem cell transplantation may allow doctor give high dos chemotherapy holmium Ho 166 DOTMP kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combine holmium Ho 166 DOTMP melphalan peripheral stem cell transplantation treat patient multiple myeloma .</brief_summary>
	<brief_title>Chemotherapy , Holmium Ho 166 DOTMP , Peripheral Stem Cell Transplantation Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine radiation absorb dose holmium Ho 166 DOTMP kidney patient multiple myeloma , base whole body gamma camera image data comparison obtain use ICRP mathematical model . - Determine average marrow dose drug patient use gamma camera whole body count patient receive drug . - Determine pharmacokinetics drug patient . - Compare marrow dose estimate determine gamma camera whole-body count thyroid uptake probe count patient receive drug . - Evaluate intra-patient variability uptake drug bone repeat test . - Determine whether biodistribution dosimetry influence administer drug bolus compare 15-minute infusion patient . - Compare reduction dose rate 15-minute infusion v bolus injection drug estimate effect kidney exposure patient . - Determine renal transit time patient bolus injection drug ass whether information improves dose estimate kidney mathematical model . - Determine whether correlation renal transit time technetium Tc 99m-diethylenetriaminepentaacetic acid ( DTPA ) holmium Ho 166 DOTMP . - Determine adverse event patient receive drug . - Determine efficacy target therapy dose holmium Ho 166 DOTMP melphalan follow autologous peripheral blood stem cell transplantation patient . OUTLINE : This multicenter study . Patients enter one two cohort . - Cohort A : Patients receive diagnostic dose holmium Ho 166 DOTMP IV 15 minute day 1 IV bolus day 8 . - Cohort B : Patients receive diagnostic dose holmium Ho 166 DOTMP IV 15 minute day 1 8 . After diagnostic dose , patient cohort also undergo gamma camera image whole body day 1 8 . Approximately 1-3 week later , patient cohorts demonstrate adequate uptake first diagnostic dose holmium Ho 166 DOTMP bone marrow receive therapeutic holmium Ho 166 DOTMP IV 15 minute day -13 -10 follow melphalan IV 20-30 minute day -10 -1 . Patients undergo autologous peripheral blood stem cell transplantation day 0 . Patients follow monthly 1 year every 3 month 1 year . PROJECTED ACCRUAL : A minimum 12 patient ( 6 per cohort ) accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma ( MM ) Patients prior diagnosis monoclonal gammopathy undetermined significance ( MGUS ) smolder myeloma eligible progress meet criterion diagnosis MM No nonsecretory MM No symptomatic MGUS , smolder MM , indolent MM No solitary bone extramedullary plasmacytoma No immunoglobulin M myeloma Prior induction therapy myeloma require Responding , stable , progressive disease induction therapy , relapse disease Candidate autologous hematopoietic stem cell transplantation Prior stem cell mobilization chemotherapy growth factor accord institutional procedure Availability least 2,000,000 CD34+ cells/kg PATIENT CHARACTERISTICS : Age 18 70 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin great 2 mg/dL SGPT great 2 time upper limit normal No clinical evidence amyloidosis liver Renal Creatinine great 2.0 mg/dL Creatinine clearance least 45 mL/min Renal ultrasound normal No clinical evidence amyloidosis kidney No urinary obstruction renal pelvis , ureter , bladder outlet ultrasound Cardiovascular Ejection fraction least 50 % evidence amyloidosis echocardiogram No clinical evidence amyloidosis heart No uncontrolled arrhythmia No symptomatic cardiac disease Pulmonary FEV1 , FVC , DLCO least 60 % No symptomatic pulmonary disease No clinical evidence amyloidosis lungs Other No known allergy vitamin C bisphosphonates No known hypersensitivity technetium Tc 99m phosphorus radiopharmaceutical ( e.g. , technetium Tc 99mmethylene diphosphonate ) No concurrent illness would severely limit life expectancy No symptom , physical finding , radiographic evidence cord compression No clinical evidence amyloidosis autonomic nervous system gastrointestinal tract No prior noncompliance study No malignancy within past 5 year except treated indolent skin cancer carcinoma situ cervix HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics No prior stem cell bone marrow transplantation No concurrent maintenance therapy comprise interferon thalidomide Chemotherapy See Disease Characteristics Endocrine therapy See Disease Characteristics No concurrent maintenance therapy comprise dexamethasone Radiotherapy No prior cumulative externalbeam radiotherapy ( EBRT ) 20 % bone marrow No prior cumulative EBRT dose 30 Gy spinal cord No prior radiotherapy bladder Surgery See Disease Characteristics Other At least 4 week since prior investigational agent MM At least 4 week since prior experimental therapy condition No bisphosphonates least 4 week study , study , least 30 day posttransplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>